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Background: Granulomatous–lymphocytic interstitial lung disease (GLILD) is a rare,
potentially severe pulmonary complication of common variable immunodeficiency
disorders (CVID). Informative clinical trials and consensus on management are lacking.
Aims: The European GLILD network (e-GLILDnet) aims to describe how GLILD is
currently managed in clinical practice and to determine the main uncertainties and
unmet needs regarding diagnosis, treatment and follow-up.org November 2020 | Volume 11 | Article 6063331
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Frontiers in Immunology | www.frontiersin.Methods: The e-GLILDnet collaborators developed and conducted an online survey
facilitated by the European Society for Immunodeficiencies (ESID) and the European
Respiratory Society (ERS) between February–April 2020. Results were analyzed using SPSS.
Results: One hundred and sixty-one responses from adult and pediatric pulmonologists
and immunologists from 47 countries were analyzed. Respondents treated a median of 27
(interquartile range, IQR 82–maximum 500) CVID patients, of which a median of 5 (IQR 8–
max 200) had GLILD. Most respondents experienced difficulties in establishing the
diagnosis of GLILD and only 31 (19%) had access to a standardized protocol. There
was little uniformity in diagnostic or therapeutic interventions. Fewer than 40% of
respondents saw a definite need for biopsy in all cases or performed bronchoalveolar
lavage for diagnostics. Sixty-six percent used glucocorticosteroids for remission-induction
and 47% for maintenance therapy; azathioprine, rituximab and mycophenolate mofetil
were the most frequently prescribed steroid-sparing agents. Pulmonary function tests
were the preferred modality for monitoring patients during follow-up.
Conclusions: These data demonstrate an urgent need for clinical studies to provide more
evidence for an international consensus regarding management of GLILD. These studies
will need to address optimal procedures for definite diagnosis and a better understanding
of the pathogenesis of GLILD in order to provide individualized treatment options. Non-
availability of well-established standardized protocols risks endangering patients.Keywords: CVID, GLILD, interstitial lung disease, e-GLILDnet, diagnosis, follow-up, treatmentINTRODUCTION
Common variable immunodeficiency (CVID) disorders are
the most prevalent symptomatic primary immunodeficiency
(PID) conditions, characterized by hypogammaglobulinemia
together with an increased susceptibility to infections and/or,
in a minority of patients, clinically significant immune
dysregulation (1). Immune dysregulation includes autoimmune
and autoinflammatory conditions, lymphoproliferative disease
and can result in both solid organ and hematologic malignancies.
With generally efficacious administration of immunoglobulin
substitution and antimicrobial agents, immune dysregulation
now imposes the heaviest burden on morbidity and mortality
of CVID patients. The term “CVID” was in 2009 redefined by the
International Union of Immunological Societies Expert Primary
Immunodeficiency Committee into “CVID disorders”,
emphasizing the heterogeneity of this collection of inborn
errors of immunity (2). The number of potential distinct
entities within this group remains unknown and although
novel monogenic forms are still being identified, the majority
of cases is assumed to be of complex and polygenic inheritance
(3, 4).
Lung involvement is very common in CVID disorders and
typically has two not mutually exclusive entities: structural
abnormalities such as bronchial wall thickening, air trapping
and bronchiectasis that can arise as complications of recurrent
bronchopulmonary infections; and interstitial lung disease (ILD)
including parenchymal and interstitial abnormalities (groundorg 2glass opacities, nodules and consolidation) that are considered to
be driven by intrinsic CVID-related immune dysregulation. This
ILD in CVID disorders is commonly referred to as
granulomatous-lymphocytic interstitial lung disease or GLILD.
The estimated prevalence of GLILD in CVID disorders is around
15% and may already be present in childhood CVID disorders
(5–7).
GLILD was defined by a UK Consortium as “a distinct
clinico-radio-pathological ILD occurring in patients with
CVID disorders, associated with a lymphocytic infiltrate and/
or granuloma in the lung, and in whom other conditions have
been considered and where possible excluded”, recognizing that
this GLILD is “usually seen in the context of multisystem
granulomatous/inflammatory involvement” (8). This definition
of GLILD was unanimously supported by all participants.
Agreement scores on other aspects of GLILD diagnosis were
lower: for instance, 47% agreed that GLILD patients need to be
symptomatic. The report went on to describe that diagnostic
evaluation should include spirometry (96% consensus), lung
volumes (91%), gas transfer (100%), flexible bronchoscopy to
exclude infection (83%), surgical lung biopsy (83%) and
computed tomography (CT, all respondents). Consensus was
defined that lung biopsy specimens should be stained for CD3,
CD4, CD8, CD20, for the presence of bacteria including
Mycobacteria and for fungi, and for clonality to exclude
lymphoma (8).
The pathogenesis of GLILD remains unclear and is
considered to be heterogeneous. Histologic studies revealNovember 2020 | Volume 11 | Article 606333
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formation of tertiary lymphoid structures. Increased
concentrations of local and serum B-cell activating factor
(BAFF) possibly drive B-lymphocyte hyperplasia (9).
GLILD is a rare condition and therefore there is a lack of
robust scientific evidence, especially about therapeutics. There
are currently no published randomized controlled trials or
prospective cohort studies investigating the effects of
immunomodulatory treatments as many difficulties arise in
recruiting an adequate number of participants. A systematic
review is included in this collection (Lamers et al., this issue).
Current investigations are exclusively observational studies; this
is problematic as they are unable, by design, to include
randomization and concealment of allocation (10).
The first step in GLILD treatment consists of optimization
of CVID disorders management, including Ig replacement
therapy (IgRT). Antimicrobial prophylaxis may be used in a
proportion of patients, with initiation of immunosuppressive
therapy given that IgRT alone is not generally effective to treat
GLILD (11–15). As with many inflammatory conditions,
corticosteroids are often the first choice for remission
induction in GLILD. Corticosteroids often result in an
improvement in GLILD, however following prednisolone
therapy of 1–4 months a widely heterogeneous response was
observed, as many patients do not exhibit any improvements
in PFTs or had disease flares upon tapering of corticosteroid
medication (16). Collectively, these findings define the need
for re-evaluation of corticosteroid monotherapy as first-
line treatment.
Regarding second-line immunosuppressive therapy, various
drugs have been employed. Small case series (17) and single case
reports (18–21) show a potential effect of rituximab as
monotherapy. Rituximab is also documented to be used in
combination with azathioprine (21–28), 6-MP (22, 29) or
mycophenolate mofetil (22, 28, 30), supporting a role for B-
lymphocytes in the pathogenesis of GLILD. Other therapies
include conventional disease modifying anti-rheumatic drugs
(cDMARD), such as cyclophosphamide and methotrexate,
however, current evidence is limited and lacks scientific
support through a lack of controlled clinical trials (31). We are
not aware of any reports using novel anti-fibrotics used in
fibrotic ILD such as nintedanib and pirfenidone.
The scarcity and low level of quality of scientific literature on
GLILD highlights knowledge gaps in essential aspects of GLILD,
including pathogenesis, diagnostic evaluation and therapy. Since
GLILD is a rare disease, these data can only be obtained by
means of constructive, multicenter and multidisciplinary
collection and collaboration.
With this aim, the e-GLILDnet was established in 2019 as a
Clinical Research Collaboration of the European Respiratory
Society (https://www.ersnet.org/research/e-glildnet—a-
european-granulomatous-lymphocytic-interstitial-lung-disease-
network; twitter: @glildnet) (32). A first workstream of this
group was to conduct an online questionnaire among treating
physicians of which the results are described here.Frontiers in Immunology | www.frontiersin.org 3METHODS
An online questionnaire was distributed to members of the
European Respiratory Society (ERS) and European Society for
Immunodeficiencies (ESID) between February 19 and April 30,
2020, and promoted on Social Media.
The questionnaire was developed by the e-GLILDnet
collaborators and pretested. Questions were designed by
authors with experience in immunology (AV, KW) and
pulmonology (TA, JH) and previous experience in designing
online questionnaires (KW) (33) Multiple rounds of revision
within this author group and subsequently the entire e-
GLILDnet team followed. Final adjustments were made after
testing an online pilot version. The questionnaire was distributed
(in English), and comprised 35 combined open/multiple choice
questions focusing on screening, diagnosis, treatment and
follow-up of GLILD.
After April 30, 2020, data were collected and categorized for
further analysis. Data were transferred and stored in an
electronic database of IBM SPSS Statistics (version 23) for
Windows, Armonk NY. Statistical analyses consisted of
descriptive statistics and comparison of categorical data using
Pearson Chi square or Fischer exact tests. A p value of < 0.05 was
considered statistically significant.RESULTS
Clinicians Treating GLILD Rarely Have
Access to Standardized Protocols
A total of 161 substantially completed clinician surveys were
returned. Responses came from 47 different countries, most
frequently Italy (n=17), followed by France, Spain, United
Kingdom (each n=14) and Australia, Czech Republic,
Germany, Portugal and the U.S.A. (each n=5).
The majority (n=127, 78.9%) of respondents treated adult
patients and were specialized in either pulmonology (n=81,
50.3%) or immunology (n=38, 23.6%). Other specialties (n=11,
6.8%) included internal medicine and infectious diseases. The 31
responding pediatricians were specialized in immunology (n=24,
14.9%) or pulmonology (n=7, 4.3%) and two additional
respondents treated both adult and pediatric immunology
patients. The responses from these two subjects were analyzed
in both groups for descriptive statistics but excluded from
comparisons between those treating adult and pediatric patients.
Respondents treated a median of 27 (range 0 to 500) CVID
disorders patients and 5 (0 to 200) GLILD patients with a large
variation between respondents. Only a small proportion (n=11,
6.8%) worked at a secondary care hospital, the majority was
employed at specialized settings including tertiary care hospitals
(n=82, 50.9%) and/or reference centers for PID/CVID disorders
(n=61, 37.9%) or ILD/sarcoidosis (n=56, 34.8%). More pediatricians
worked at a PID reference center (58.1% vs 33.1%; p = 0.01) and/or
in an academic setting (77.4% vs 44.9%, p=0.001) than specialists
treating adults. Conversely, there were no pediatricians employed atNovember 2020 | Volume 11 | Article 606333
van de Ven et al. Management of GLILDILD/sarcoidosis references centers, compared to 44.1% of the adult
specialists (p<0.001).
Despite these specialized work environments, only 19.3% of
respondents reported the availability of a dedicatedGLILD protocol.
The Diagnosis of GLILD Is Often Difficult
When asked about screening for lung disease in CVID disorders
patients with no established structural lung disease (i.e. GLILD
and/or airway disease), most respondents stated using
pulmonary function tests at least once a year (n=110, 70.9%).
Chest CT was less frequently used, with 63.2% of respondents
using CT for screening in asymptomatic patients at intervals
between ≥1–3 years up to every 5–10 years. Immunologists (75.4
vs 54.8% for pulmonologists, p=0.008) and those working at PIDFrontiers in Immunology | www.frontiersin.org 4reference centers (83.3 vs 50.5%, p<0.001) reported greater use of
CT screening. There were no differences between pediatricians
and those caring for adults (64.3 vs 63.2%, p=0.548). Nearly all
respondents (94.4%) admitted having at least sometimes
difficulties diagnosing GLILD, with 38.3% stating that GLILD
diagnosis was often difficult. These difficulties were similar
between different specialties and centers.
The tests used for the evaluation of suspected GLILD are
described in Table 1. Whilst not definitive, the majority of
clinicians reported using sputum and bronchoalveolar lavage
(BAL) tests, and half of them used blood investigations. The use
of biopsy was much less frequent: 46 respondents (28.6%) stated
that histology is required for diagnosis, but 71.4% would not
routinely undertake a biopsy. Respondents were questioned on
the results from biopsies from patients with suspicion of GLILD,
and 46 (28.9%) out of 103 stated that alternative diagnoses had
been found. Elaborating upon these alternative diagnoses,
lymphoma was most frequently reported, but malignancy or
lung cancer not further specified were also mentioned. Second
were infections, including TB, fungal infection and one case of
EBV induced lipoid pneumonia. One respondent mentioned
hypersensitivity pneumonitis. Furthermore, other conditions
mentioned included nonspecific interstitial pneumonia (NSIP),
granulomatous diseases, sarcoidosis, lymphoproliferative
disorders, post-inflammatory fibrosis and organizing
pneumonia which however may be considered part of the
spectrum of GLILD.
Disparities in Follow-Up and Criteria for
Initiation of Immunosuppressive in GLILD
Since there are no clear guidelines on how to carry out follow-up
of GLILD patients, we asked whether respondents experienced
difficulties in deciding follow-up. This question was filled out by
110 respondents, of which 18 (16.3%) mentioned that they did
not experience difficulties at all in defining adequate follow-up
for GLILD. The majority however experienced difficulties at
different aspects, namely in defining the optimal time interval
for follow-up (55.5%), defining the optimal monitoring method
(39.1%) and how to follow-up on asymptomatic patients (43.6%)
and patients that did not require current treatment (24.5%).
We asked how follow-up of asymptomatic patients not requiring
therapy was carried out with regard to monitoring methods and
time interval (Table 2). The same questions were asked for patientsTABLE 1 | Performed diagnostics in the evaluation of suspected GLILD/
exclusion of other pathology.
No. (total 161) Percentage (%)
Blood 118 73.3
Aspergillus antigen blood test 80 49.7
Mycobacterium blood test 80 49.7
Beta D glucan blood test 41 25.5
Other blood tests* 33 20.5
Sputum 121 75.2
Bacteria 108 67.1
Mycobacteria 108 67.1
Fungal pathogens 90 55.9
Viral pathogens 43 26.7
Other sputum tests 5 3.1
Bronchoalveolar lavage 129 80.1
Bacteria 124 77
Mycobacteria 121 75.2
Fungal pathogens 119 73.9
Viral pathogens 87 54
Other bronchoalveolar lavage tests** 39 24.2
Lung biopsy 39 24.2
Bacteria 22 13.7
Mycobacteria 30 18.6
Fungal pathogens 26 16.1
Viral pathogens 17 10.6
Other biopsy tests 11 6.8*Other blood tests include culture, autoantibody panel, beta 2 microglobulin, soluble
CD25, cytology differential, Igs, procalcitonin, PCR EBV, and CMV. **Other
bronchoalveolar lavage tests include next generation sequencing of pathogens,
galactomannan, flow cytometry.TABLE 2 | Preferred monitoring time intervals for untreated and treated patients per modality.
Asymptomatic, untreated GLILD patients GLILD patients requiring treatment
1st choice 2nd choice 1st choice 2nd choice
Clinical and laboratory evaluation 3–4 monthly
(n = 46, 40.4%)
6–8 monthly
(n = 41, 36%)
3–4 monthly
(n = 58, 50.9%)
1–2 monthly
(n = 42, 36.8%)
PFT 6–8 monthly
(n = 52, 44.8%)
12 monthly
(n = 37, 31.9%)
3–4 monthly
(n = 67, 58.3%)
6–8 monthly
(n = 28, 24.3%)
CXR 12 monthly
(n = 28, 26.9%)
6–8 monthly
(n = 21, 19.6%)
3–4 monthly
(n = 32, 31.4%)
6–8 monthly
(n = 14, 13.7%)
HRCT >12 monthly
(n = 61, 53.5%)
12 monthly
(n = 40, 35.1%)
6–8 monthly
(n = 40, 35,4%)
12 monthly
(n = 32, 28,3%)November 2020 | Volume 1CXR, chest X-ray; GLILD, granulomatous–lymphocytic interstitial lung disease; HRCT, high-resolution computed tomography; PFT, pulmonary function tests.1 | Article 606333
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116 respondents. As expected, the selected time intervals were on
average shorter than for patients not requiring therapy. Chest X-ray
was not considered to be an applicable monitoring method by 35%
of the respondents. A different subset of respondents however
seemed to value chest X-ray for monitoring patients requiring
therapy; of the 66 respondents that used CXR in this group,
almost half of them (n=32; of which 22 were adult
pulmonologists) applied this modality every 3 to 4 months.
Clear-cut criteria on when to initiate immunosuppressive
therapy in GLILD have not been defined and this was reflected
in the dissimilar answers given to this question. A diagnosis of
GLILD alone was for the majority of respondents (n=82 out of
103, 79.6%) not sufficient reason to start an immunosuppressive
treatment regimen. Similarly, the presence of clinical symptoms
alone (n=86, 83.5%) or deteriorating PFT (n=80, 77.6%) or
HRCT findings (n=77, 74.8%) alone was usually insufficient
basis for commencement of therapy. The fraction of
respondents that would initiate therapy increased if there were
abnormalities in two out of three of the aforementioned items
but remained relatively low; (31.1% for clinical symptoms and
PFT decline; up to 47.6% for HRCT and PFT deterioration).
Strikingly, only 60.2% would treat “All patients with impaired
lung function, clinical symptoms and worsening of CT scan”.
Adult pulmonologists (75%) were most likely to initiate
treatment in this patient category, followed by adult
immunologists (60%) and pediatricians (12.5%).
Therapy of GLILD꞉ Variable Use of
Steroids for Remission-Induction
and Maintenance Therapy
The next part of the survey included questions related to the
treatment of GLILD. Respondents were questioned whether they
had used glucocorticoids for remission induction and/or
maintenance therapy in GLILD patients and if so, in how
many patients. Of the 125 respondents that filled out this
quest ion, 82 (65 .6%) had used monotherapy with
glucocorticoids for remission induction. This was equally
distributed between adult immunologists and pulmonologists.
The majority (n=63, 77.8%) had used this regimen in 1–5
patients; ten (12.3%) and eight (9.9%) clinicians had treated 5–
10 or >10 patients, respectively. Questions on dosage and
tapering revealed that the commonest regimen for severe
GLILD was 1mg/kg body weight (BW), as performed by 50%,
but 0.5 mg/kg BW was also frequent (32/82 respondents, 39.0%).
Only one respondent used a dose lower than 0.5mg/kg BW and
some clinicians used more than 1mg/kg BW. The twelve
responding pediatricians used significantly higher doses than
clinicians treating adults only; six of them used 1mg/kg BW and
the other six used >1mg/kg BW (p<0.001, Pearson Chi-square).
The distribution of the tapering period of glucocorticoids was
comparable between groups; most physicians (n=38, 46.3%)
tapered glucocorticoids entirely or until maintenance dose
within 1–3 months, but longer or more variable intervals were
also reported. The experience on effectiveness of this therapy was
diverse: only three respondents (3.7%) replied that nearly allFrontiers in Immunology | www.frontiersin.org 5patients responded; in general, respondents felt that the majority
of (n=47, 58.0%) or some patients (n=27, 33.3%) responded.
The proportion of respondents that used glucocorticoids for
maintenance therapy was 58 out of 124 (46.8%). Noticeably, six
of them did not report using glucocorticoids for remission
induction. Again, patient numbers treated by individual
clinicians were small with 1–5 patients for the majority (n=47,
82.5%) of clinicians. About two-third used ≤7.5mg steroids daily
and slightly under one-third used 7.6–15mg per day. Three
respondents had used maintenance doses >15mg/day. The
clinical response to these maintenance glucocorticoids was
heterogeneous and many responded with multiple answers;
complete and partial responses to maintenance glucocorticoids
were noted by 20 and 62.7% of 59 respondents, respectively. A
sustained response was seen by 16 (27.1%), but relapses occurred
frequently as well (n=20, 33.8%).Therapy of GLILD꞉ Azathioprine,
Rituximab and Mycophenolate Mofetil
Are the Most Frequently Employed
Steroid-Sparing Agents
Following the questions on glucocorticoid use, respondents were
asked on their experience with other immunosuppressive agents
for treatment of GLILD. These included both cDMARD,
biologicals such as rituximab, TNF inhibitors and
combinations of both. Respondents were asked to rank these
drugs according to their personal practice (Figure 1A). Figure
1A shows that the three most commonly applied non-steroidal
immunosuppressants were azathioprine, rituximab and
mycophenolate mofetil. Noticeably, mycophenolate mofetil was
frequently ranked as second choice, usually after azathioprine.
Other immunosuppressants used included sirolimus,
cyclosporine, and individual cases of ruxolitinib and tofacitinib.
The majority of respondents had used these drugs only in up to
five and occasionally up to 10 patients. Only azathioprine (n=2),
MMF (n=1),MTX (n=1) and RTX (n=1) were used inmore than 10
patients. Respondents were asked to elaborate on their experience
with the immunosuppressants they had ranked first and second.
The cumulative responses for the top five non-steroidal agents are
shown in Figure 1B. Noticeably, although azathioprine was the first
choice for most respondents, its perceived effectiveness appeared
less favorable than for other drugs; particularly the combination of
rituximab with mycophenolate mofetil, but also mycophenolate
mofetil alone appeared to induce a response in a larger proportion
of the patients. These findings suggest that the choice of drug is not
solely based on its expected clinical effectiveness but that other
factors are involved; indeed, some respondents mention the costs
and availability of rituximab in particular as limiting factors. These
answers corresponded with the answers given to the question
whether clinicians would discourage the prescription of the
particular drug. Mycophenolate mofetil, rituximab and the
combination of these two were less likely to be discouraged.
Drugs were often discouraged for multiple reasons; usually side
effects, but also other effects or ineffectiveness. Hydroxychloroquine
was usually discouraged due to a lack of effect.November 2020 | Volume 11 | Article 606333
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were enquired to comment on the use of antimicrobial prophylaxis
to prevent Pneumocystis jiroveci pneumonia (PCP). Answers were
categorized into different categories as shown in Figure 2. The
prescription of PCP prophylaxis was very heterogeneous, both
within and between specialties. PCP prophylaxis appeared to be
more frequently applied by adult specialists than by pediatricians,
but the differences were not statistically significant. Various
comments were given if the option “other” was chosen. PCP
prophylaxis was often individualized and based on (combinations
of) CD4+ T cell counts, duration of immunosuppressive therapy
and combinations of immunosuppressants, particularly the
combination of a DMARD with systemic glucocorticoids.Frontiers in Immunology | www.frontiersin.org 6DISCUSSION
We present the results of an online clinician survey related to the
diagnosis and management of GLILD. We received 161
responses from physicians caring for GLILD patients all over
the world. The results show that there are many areas of need
and uncertainty on this topic that deserve attention.
The diagnosis of GLILD is often difficult and most
respondents did not have access to a GLILD protocol. CVID
disorders patients were often not regularly screened for GLILD
using PFT and less frequently by CT. Once GLILD was
considered, the diagnosis was usually based on PFT and CT,
aided by exclusion of infection via auxiliary blood, sputum andA
B
C
FIGURE 1 | Immunosuppressive therapy in GLILD. (A) Top-three ranking of non-steroidal immunosuppressive drugs. (B) Estimated patient response rates to the 5
most highly ranked non-steroidal immunosuppressive agents according to the treating clinicians. (C) Percentage of respondents that would encourage the use of the
non-steroidal immunosuppressive drug. Aza, azathioprine; HCQ, hydroxychloroquine; MMF, mycophenolate mofetil; MTX, methotrexate; RTX, rituximab.November 2020 | Volume 11 | Article 606333
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Immunological BAL analysis was not frequently used, likely due
to its uncertain value in the diagnosis of GLILD. The majority of
respondents experienced difficulty defining adequate follow-up
of GLILD patients. Especially, imaging monitoring would benefit
from guidelines with considerable heterogeneity in the use and
interval of examinations by X-ray and chest CT. Most of these
findings are in line with the results of the British Lung
Foundation (BLF) survey conducted among UK centers (8),
which showed overall consensus regarding the original work-
up of GLILD but failed to define consensus related to
management strategies and the initiation of therapy in certain
patient groups such as asymptomatic GLILD.
Regarding therapy, corticosteroids remain the first line of
immunosuppressive induction therapy for the majority of
respondents, as is common practice in literature and clinical
setting (8, 15). About half of respondents of the BLF survey also
use corticosteroids in low dosages to maintain remission. Of those
respondents, 46% preferred non-steroidal immunosuppressive
monotherapy, 13% corticosteroids alone, 21% a combination of
both and 13% complete withdrawal andmonitoring. The fact that in
our cohort 33% uses a maintenance dose of >7.5 mg/d of
prednisone may already hint towards the difficulty of choosing an
alternative second line therapy.
This uncertainty is also reflected by the heterogeneous use of
non-steroidal immunosuppressive agents which includes
cDMARD, biologicals and combinations of both. Within this
study, azathioprine, mycophenolate mofetil and rituximab were
most frequently used. Indeed, for these three drugs there was
80% or greater consensus with the BLF study. However, although
part of the consensus, the frequent use of azathioprine was not
based on clinical evidence as a substantial fraction of theFrontiers in Immunology | www.frontiersin.org 7respondents did not report azathioprine as being effective in
this disease. In contrast, the combination of rituximab with
azathioprine first promoted by the early paper of Chase and
colleagues (22) has been used successfully in several patients. The
successful induction of radiological and spirometric
improvement by a combination of rituximab with azathioprine
or mycophenolate mofetil was confirmed in a recent extension
and expansion of the original Chase study reporting
retrospectively 39 GLILD patients with and without an
underlying monogenetic defect (28).
In addition to a lack of evidence regarding optimal
immunosuppressive therapy, the question of whether PCP
prophylaxis should be employed and, if so, in which patients,
remains to be answered. Antimicrobial prophylaxis was
considered beneficial in a meta-analysis of a heterogeneous
population of non-HIV immunocompromised patients (34).
As most of these patients had both impaired humoral and
cellular immune responses due to acute leukemia or organ
transplantation, it remains unclear whether these findings
could and should be extrapolated to all GLILD patients. The
variable PCP prophylaxis strategies in our survey reflect the lack
of recommendations for non-HIV immunocompromised
patients. Typically, the decision is made for each case
individually, including factors such as combination and
duration of immunosuppressive regimen, numbers of CD4+ T
lymphocytes and perhaps other elements such as age,
comorbidities and physician’s preferences.
The strengths of this study include a high response rate of 161
valuable responses from 47 countries, making this the largest
survey on this topic until now. Respondents represented six
continents and worked in the relevant specialties of pulmonology
and immunology for both pediatric and adult patients. TheseFIGURE 2 | Prescription of Pneumocytis jiroveci pneumonia (PCP) antimicrobial prophylaxis varies within and between specialties. IS, immunosuppression.November 2020 | Volume 11 | Article 606333
van de Ven et al. Management of GLILDfindings thus provide an adequate reflection of the real practice
of managing GLILD in CVID disorders. Detailed responses were
provided on multiple relevant subjects, including diagnosis,
follow-up and therapy.
Despite our high number of responses, it still represents only
a small proportion of the actual population of clinicians that take
care of these patients. Hence, certain selection bias cannot be
excluded. Additionally, the completeness of the answers is a
limitation as it varied from ~65% to 100%. Particularly the
section on therapy of GLILD was incomplete and filled out by
around two-thirds of the respondents. This can be due to the
length of the survey and the fact that treatment is generally
carried out in multidisciplinary teams. Additionally, respondents
may not feel comfortable regarding their experience with
treatment of GLILD, as patient numbers were low and
respondents appeared habitually reluctant to initiate therapy
and treatment. Finally, this survey shows that a major
limitation of current GLILD management is the lack of
evidence, for which consensus is a poor substitute. There is a
clear need for basic, translational and clinical research in order to
eventually establish evidence-based guidelines. Basic research
into the pathogenesis of GLILD should aim to elucidate the
complex interplay between immune system, local micro-
environment of the lungs and microbes (35) and host-microbe
interactions. These findings may allow for development of
targeted therapies, or optimization of the use of available drugs
for improved efficacy and reduced toxicity. Since the clinic-
radio-pathological picture of GLILD is very heterogeneous, the
pathogenesis is probably multifaceted as well. Therapy should be
optimized on the specific subtype of GLILD, perhaps eventually
guided by the cellular infiltrates on biopsy, while taking into
account other relevant factors such as toxicity, availability and
patient preferences. Despite the pressure to see patients virtually
in the current COVID-19 pandemic, this population requires
face-to-face contact including clinical and diagnostic exams.
The rarity of GLILD remains an Achilles’ heel, as further
dissection of this relatively small cohort into more homogenous
subgroups relies on international collaboration between GLILD
clinicians. Collaborative clinical studies addressing natural
disease course, prognosis and treatment outcomes ought to be
performed in multicenter, standardized settings. The
development of an expert platform to collect data should be
encouraged, as well as biobanking of biopsy specimens.
Awareness, education and the availability of facilities for low-
income countries are important additional topics.
The European Respiratory Society recognizes these needs and
supported the launch of a Clinical Research Collaboration onFrontiers in Immunology | www.frontiersin.org 8GLILD, the e-GLILDnet (https://www.ersnet.org/research/e-
glildnet—a-european-granulomatous-lymphocytic-interstitial-
lung-disease-network; twitter: @glildnet). The e-GLILDnet aims
to bring together clinicians, researchers and patients
representatives from across Europe to improve the lives of
those living with GLILD.
In conclusion, our survey data demonstrate an urgent need
for clinical studies to provide more evidence for an international
consensus regarding diagnosis and management of GLILD. The
e-GLILDnet will support and facilitate this aim by supporting
international collaboration, particularly on studies addressing
optimal procedures for definite diagnosis and a better
understanding of the pathogenesis of GLILD in order to
provide individualized treatment options.DATA AVAILABILITY STATEMENT
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